Award of the Maresch-Klingelhöffer Prize
Prof. Jindrich Cinatl, Dr. Constanze Schneider, Dr. Jürgen Vogt
As part of the ceremony to mark the 25th anniversary of the Frankfurt Foundation for Children with Cancer in November 2019, Dr. Constanze Schneider was awarded the Maresch-Klingelhöffer Prize.
The prize has been awa…
New insights into ALL therapy
Mystery of anticancer drug nelarabine for leukaemia treatment solved
Acute lymphoblastic leukaemia (ALL) is the most common cancer in children. With the active substance nelarabine, T-ALL, a subtype that resembles T-lymphocytes, can be treated well. However, B-ALL, a subtype tha…
Interview with Prof. Dr. Jindrich Cinatl
Read here the detailed interview published in the magazine “Wissen wird” of the University Hospital Frankfurt, issue 2/2020, in December 2020.
Research helps – Not only now
Childhood cancer hits everyone involved like a “bolt from the blue”. From one moment to the next, the view of the world changes, the focus of life shifts. The affected child, the parents, even the entire environment usually fall into a “deep hole”. Despair and struggling with fa…
Visualizing Molecular Patterns of Membrane TNF Receptors using single-molecule microscopy
The question of whether a sick cell dies, divides, or travels through the body is regulated by signal molecules that bind and activate receptors on the cell membrane. Among the most important molecular cues in the immune system is Tumor Necrosis Factor α (TNFα) that binds to TNF…
25 years plus 1 – A review
In September 1994, the Frankfurt Foundation for Children with Cancer was established with the aim of developing new therapy concepts and treatment options for children with cancer. In November 2019, under the patronage of Hesse’s Prime Minister Volker Bouffier, it celebrated its…
Blood cancer: When drugs work
New marker found for the treatment of leukaemia patients
Patients suffering from acute myeloid leukaemia (AML) – a certain form of blood cancer – are treated with the help of chemotherapy. Often, the active substances Decitabine and Azacitidine – so-called DNA methyltransferase…
Financial resources for research
Dr. Sjoerd van Wijk, group leader at the Institute of Experimental Cancer Research in Pediatrics, received a research grant from the German Research Foundation (DFG) to further expand his own research group working on the regulation of ubiquitination in cell fate control. Previo…
